US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

692.98

+18.812.79%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:701.32

Open:678.06

Low:664.82

Close:674.17

Volume:35.86M

Turnover:761.83M

Market Cap:21.43B

Float Cap:15.84B

Loading ...

Tempus AI CFO James William Rogers Sells 11,529 Common Shares for $634,095

CRISPR Gene Editing Therapy Shows Groundbreaking Efficacy in Pediatric Patients

FMR Reports $10.04 Million Beam Therapeutics Common Share Sale

HCA Healthcare announces research published in NEJM on CRISPR-based therapy

tempus AI Inc Class A call volume above normal and directionally bullish

Tempus AI Launches Angiosarcoma Research Collaboration with Angiosarcoma Awareness

Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Simply Wall St.

Recursion Pharmaceuticals director Bumpus Namandje disposes of 3,963 common shares worth $12,599.34

Thanks to SpaceX, Index Funds Won't Track Each Other as Closely. Here's One Pro's Advice. -- Barrons.com

Can Tempus AI’s (TEM) New ECG-AF Validation Deepen Its Edge in Clinical-Grade Healthcare AI?

Simply Wall St.

Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial

Simply Wall St.

Recursion Shareholders Reelect Directors and Approve Governance Matters

Recursion Pharmaceuticals holds annual shareholder meeting

Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":692.97644,"timestamp":1782763199999,"preClose":674.1668,"halted":0,"volume":35859109,"delay":0,"changeRate":0.027901,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":18.809631,"latestTime":"06-29 16:00:00 EDT","open":678.06036,"high":701.3177,"low":664.8196,"amount":761832702.990477,"amplitude":0.054138,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782826200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.685544,"peRate":-13.833081,"turnoverRate":0.05126,"increases":4,"decrements":0,"flats":0,"marketCap":21433034112,"floatMarketCap":15840153856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":701.3177,"amplitude":0.054138,"preClose":674.1668,"low":664.8196,"pbRate":"4.685544","latestPrice":692.97644,"volume":35859109,"delay":0,"open":678.06036,"prevYearClose":658.3995,"prevWeekClose":674.1668,"prevMonthClose":647.3484,"prevQuarterClose":542.5347,"fiveDayClose":632.4122,"twentyDayClose":647.3484,"sixtyDayClose":556.9229,"secType":"PLATE","market":"US","turnoverRate":0.05126,"peRate":-13.833081,"marketCap":21433034112,"floatMarketCap":15840153856,"timestamp":1782763199999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647834325","title":"Tempus AI CFO James William Rogers Sells 11,529 Common Shares for $634,095","url":"https://stock-news.laohu8.com/highlight/detail?id=2647834325","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647834325?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:40","pubTimestamp":1782780039,"startTime":"0","endTime":"0","summary":"Tempus AI CFO James William Rogers sells 11,529 common shares for $634,095Tempus AI CFO James William Rogers sold 11,529 shares of Class A common stock on June 25, 2026 at USD 55.Direct holdings fell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL14H8Mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CFO James William Rogers Sells 11,529 Common Shares for $634,095","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","BK4613","BK4611","LU1861559042.SGD","TEMT","BK4121","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167664576","title":"CRISPR Gene Editing Therapy Shows Groundbreaking Efficacy in Pediatric Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1167664576","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167664576?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:00","pubTimestamp":1782763234,"startTime":"0","endTime":"0","summary":" HCA Healthcare Inc (HCA) announced on Monday that a gene editing therapy study it participated in has been published in the New England Journal of Medicine, showing positive results for children...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU0433182093.SGD","SG9999014013.SGD","LU1861559042.SGD","SG9999014005.SGD","LU0882574055.USD","SG9999014021.USD","SG9999014039.USD","LU0130102774.USD","LU2355687059.USD","LU0878866978.SGD","BK4588","IE00B775SV38.USD","LU0211328371.USD","LU1150488135.SGD","LU1119994496.HKD","BK4611","LU0980610538.SGD","LU1084165304.USD","LU2244417387.USD","LU0708994859.HKD","LU1267930490.SGD","HCA","LU0128525929.USD","LU1261432733.SGD","LU0868494617.USD","LU1267930573.SGD","LU0068578508.USD","CRSP","IE00B3S45H60.SGD","LU0985489474.SGD","LU1150488218.USD","BK4556","BK4585","BK4185","LU0029864427.USD","BK4139","LU0310800379.SGD","LU0211327993.USD","LU1861558580.USD","LU0648001328.SGD","LU0310799852.SGD","LU1201861249.SGD","LU0203345920.USD","LU0187121727.USD","BK4504","LU1489326972.SGD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647094643","title":"FMR Reports $10.04 Million Beam Therapeutics Common Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2647094643","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647094643?lang=en_us&edition=fundamental","pubTime":"2026-06-30 02:18","pubTimestamp":1782757081,"startTime":"0","endTime":"0","summary":"FMR reports $10.04 million Beam Therapeutics common share saleFMR sold 284,860 Beam Therapeutics common shares on June 25-26 at weighted average prices of $35.12 and $35.26.Stake held via F-Prime Capi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL6tBkfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"FMR Reports $10.04 Million Beam Therapeutics Common Share Sale","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4535","LU1861558580.USD","LU1861559042.SGD","BK4505","BK4139","BK4556","BK4585","BK4588","BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647022371","title":"HCA Healthcare announces research published in NEJM on CRISPR-based therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647022371","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647022371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:35","pubTimestamp":1782736519,"startTime":"0","endTime":"0","summary":"HCA Healthcare (HCA) announced new research published in The New England Journal of Medicine, NEJM, demonstrating promising results from a gene-edi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hca-healthcare-announces-research-published-in-nejm-on-crispr-based-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hca-healthcare-announces-research-published-in-nejm-on-crispr-based-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0868494617.USD","LU0130102774.USD","LU1119994496.HKD","LU0114720955.EUR","LU1150488218.USD","HCA","LU0310799852.SGD","XBI","LU0203347892.USD","SG9999014039.USD","XLV","BK4585","SG9999014013.SGD","IE00B3S45H60.SGD","LU0878866978.SGD","LU1489326972.SGD","LU0310800379.SGD","LU0985489474.SGD","LU0980610538.SGD","LU1150488135.SGD","SG9999014021.USD","LU0211327993.USD","LU1084165304.USD","BK4504","BK4185","BK4581","LU0187121727.USD","LU2244417387.USD","LU1861559042.SGD","BK4556","BK4588","BK4139","CRSP","IE00B775SV38.USD","LU0068578508.USD","LU0029864427.USD","LU0708994859.HKD","LU1267930490.SGD","LU0211328371.USD","SG9999014005.SGD","LU0433182093.SGD","LU1861558580.USD","LU1201861249.SGD","LU0128525929.USD","LU0203345920.USD","LU1261432733.SGD","LU2355687059.USD","LABU","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646884809","title":"tempus AI Inc Class A call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2646884809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646884809?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:05","pubTimestamp":1782396310,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in tempus AI (TEM) Inc Class A with 14,319 calls trading, 3x expected, and implied vol increasing over 1 point to 78.4...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TEM","LU1861559042.SGD","BK4611","BK4613","TEMT","LU1861558580.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646680832","title":"Tempus AI Launches Angiosarcoma Research Collaboration with Angiosarcoma Awareness","url":"https://stock-news.laohu8.com/highlight/detail?id=2646680832","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646680832?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:30","pubTimestamp":1782390659,"startTime":"0","endTime":"0","summary":"Tempus AI launches angiosarcoma research collaboration with Angiosarcoma AwarenessTempus AI launched a research collaboration with Angiosarcoma Awareness to speed data-driven research in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL7rnRc8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","BK4121","BK4611","LU1861559042.SGD","TEM","LU1861558580.USD","BK4613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646847979","title":"Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646847979?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:25","pubTimestamp":1782347113,"startTime":"0","endTime":"0","summary":"20:24 EDT Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-260k-shares-of-recursion-pharmaceuticals-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-260k-shares-of-recursion-pharmaceuticals-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4544","BK4585","BK4588","BK4548","ARKK","RXRX","BK4539","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365843","title":"Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365843","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646365843?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:32","pubTimestamp":1782322362,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) stock is in focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy targeting phenylketonuria, a rare inherited metabolic disorder.\nSee our latest analysis for Beam Therapeutics.\nBeam Therapeutics shares trade at US$33.20 after a 1 day share price decline of 6.56%, while the 30 day share price return of 15.92% and 1 year total shareholder return of 93.59% point to momentum that has recently strengthened around...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BEAM","BK4556","BK4139","BK4505","BK4588","LABU","BK4585","BK4611","LU1861559042.SGD","LU1861558580.USD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645070554","title":"Recursion Pharmaceuticals director Bumpus Namandje disposes of 3,963 common shares worth $12,599.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2645070554","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645070554?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:33","pubTimestamp":1782160381,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals director Bumpus Namandje received 88,424 Class A common shares on June 17, 2026 for USD 0.Namandje sold 3,963 Class A common shares on June 18, 2026 at USD 3.18.Holdings stood at 127,632 Class A common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL7QpRTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals director Bumpus Namandje disposes of 3,963 common shares worth $12,599.34","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4548","RXRX","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645711010","title":"Thanks to SpaceX, Index Funds Won't Track Each Other as Closely. Here's One Pro's Advice. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2645711010","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645711010?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:47","pubTimestamp":1782150420,"startTime":"0","endTime":"0","summary":"In the pre-SpaceX days, it didn't really matter which major index benchmark an investor chose, whether it was constructed by Standard & Poor's, the Center for Research in Security Prices , or FTSE Russell. They all returned essentially the same amount.Over the past 25 years the range of annualized returns for the S&P 500 index, the Russell 1000 index, and the CRSP US Large Cap indexes was 9.63% to 9.72%. In other words, after 2 1/2 decades, just 0.09 percentage point, or nine basis points, separated the best performer from the worst. In dollar terms, a $1,000 investment in each of the three indexes  would have yielded terminal values that ranged from $9,880 to $10,090, a $200 difference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VEU","BK4611","VTI","SPYU","UPRO","MOAT","GSLC","ALLW","SPYD","XLG","BK4559","SPMO","SPUU","VBK","SMAX","BK4534","BK4581","ETFT","SPY","RSPA","SPDN","SPYH","SPUS","BK4139","NOBL","IVW","YSPY",".SPX","LU1861558580.USD","SFY","JEPI","SPYM","BK4564","SPXL","IVE","HIBS","RSPU","BMAY","IJH","SDS","BK4562","SPXU","HIBL","GPIX","SPHQ","SPCE","VV","BK4615","BK4585","TSPY","IJR","LU1861559042.SGD","DBSC","BK4588","VOO","CRSP","BK4187","VTV","SPGP","SCHX","SPHD","DMAX","SPYG","SPXS","RSP","XYLD","MMAX","SCHB","SPLV","SH","ACWI","SPYQ","BK4556","RSPN","SSO","ITOT","IVV","XDTE","VOOG","SPYV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645094582","title":"Can Tempus AI’s (TEM) New ECG-AF Validation Deepen Its Edge in Clinical-Grade Healthcare AI?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645094582","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645094582?lang=en_us&edition=fundamental","pubTime":"2026-06-21 10:24","pubTimestamp":1782008646,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc. recently reported a successful multi-site validation of its FDA-cleared ECG-AF software, with results published in the journal Heart Rhythm, confirming the tool’s ability to predict one-year atrial fibrillation or flutter risk in over 4,000 patients aged 65 and older. \nThis peer-reviewed evidence strengthens the clinical credibility of Tempus AI’s cardiovascular AI portfolio, highlighting how regulatory-cleared, real-world validated tools could deepen its footprint in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/can-tempus-ais-tem-new-ecg-af-validation-deepen-its-edge-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/can-tempus-ais-tem-new-ecg-af-validation-deepen-its-edge-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861559042.SGD","LU1861558580.USD","BK4121","TEMT","BK4611","BK4613","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065494","title":"Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065494","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644065494?lang=en_us&edition=fundamental","pubTime":"2026-06-20 02:42","pubTimestamp":1781894523,"startTime":"0","endTime":"0","summary":"Beam Therapeutics recently received FDA clearance for its IND application for BEAM-304, an in vivo base-editing therapy delivered via LNP infusion to correct PAH gene mutations in patients with phenylketonuria.\nThe program’s platform design, allowing multiple mutation-specific base editors to be advanced under a single clinical trial in alignment with emerging FDA guidance, could be an important proof point for Beam’s broader base-editing approach in liver diseases.\nWe’ll now explore how FDA...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-161-after-fda-clears-platfo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-161-after-fda-clears-platfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4556","BK4535","BEAM","BK4585","BK4611","LABU","LU1861558580.USD","BK4139","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644603231","title":"Recursion Shareholders Reelect Directors and Approve Governance Matters","url":"https://stock-news.laohu8.com/highlight/detail?id=2644603231","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644603231?lang=en_us&edition=fundamental","pubTime":"2026-06-19 07:39","pubTimestamp":1781825977,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). Recursion Pharmaceuticals, Inc. held its 2026 annual meeting of stockhol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-shareholders-reelect-directors-and-approve-governance-matters?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-shareholders-reelect-directors-and-approve-governance-matters?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4609","BK4139","BK4548","BK4611","BK4539","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644403979","title":"Recursion Pharmaceuticals holds annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644403979","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644403979?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:05","pubTimestamp":1781816714,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals held its annual shareholder meeting on June 17, 2026.Shareholders backed the selection of two directors for terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7NSs4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","RXRX","BK4539","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644700313","title":"Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304","url":"https://stock-news.laohu8.com/highlight/detail?id=2644700313","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644700313?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:00","pubTimestamp":1781780459,"startTime":"0","endTime":"0","summary":"FDA cleared Beam Therapeutics’ IND for BEAM-304, an in vivo base-editing therapy for phenylketonuria.Clearance enables a Phase 1/2 trial, starting with patients carrying the R408W mutation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL23sW9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2T93.GBP","BK4139","SG9999014005.SGD","BK4535","LU1861558580.USD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4611","NDAQ","LU2095319765.USD","LU2210149790.SGD","LU1861559042.SGD","BK4505","LU0314104364.USD","LU2210150020.SGD","BK4556","IE00BKPKM429.USD","BK4112","BEAM","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644570089","title":"Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2644570089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644570089?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:00","pubTimestamp":1781780401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUA8B291Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4611","BK4535","LU1861559042.SGD","BK4556","LU1861558580.USD","BK4588","BEAM","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}